Validation of the robustness of blood-based biomarkers for predicting amyloid-β positivity in Chinese populations
Blood-based biomarkers have demonstrated good robustness for predicting Aβ pathology in the Chinese population, with plasma p-tau217 standing out as the most promising marker for early detection of AD-related changes.
Authors
- Fengfeng Pan
- Lin Huang (ORCID: https://orcid.org/0000-0002-3753-7894)
- Liang Cui (ORCID: https://orcid.org/0000-0003-1112-6162)
- Qihao Guo (ORCID: https://orcid.org/0000-0001-5079-8047)
- Ying Wang (ORCID: https://orcid.org/0000-0002-6058-9131)
- Ya Miao (ORCID: https://orcid.org/0000-0003-1208-251X)
- Yihui Guan
- Zhen Zhang
Institutions
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Shanghai Sixth People's Hospital (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Frontiers in Aging Neuroscience
- Published
- 2025-12-03
- DOI
- https://doi.org/10.3389/fnagi.2025.1660755
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00